What was the main driver of the significant sales increase in the Consumer segment?

The primary driver of the Consumer segment's impressive 48.6% sales growth was the acquisition of Pfizer Inc.'s Consumer Healthcare business. This acquisition significantly boosted both total and operational sales for the segment.

How is the company managing the impact of generic competition on its pharmaceutical products?

Johnson & Johnson is actively defending its patents against generic drug filers, as detailed in the Legal Proceedings section. While some products like DURAGESIC(R) and RISPERDAL(R) are experiencing sales declines due to generic erosion, the company is also focusing on new product launches and extending exclusivity where possible, such as the pediatric exclusivity for LEVAQUIN(R) and RISPERDAL(R) oral.

What is the outlook for cost savings and capital allocation?

Johnson & Johnson announced significant cost-saving initiatives aimed at generating $1.3-$1.6 billion in pre-tax annual savings starting in 2008. In parallel, the company authorized a substantial $10 billion stock repurchase program, signaling confidence in its financial position and a commitment to enhancing shareholder value.

Are there any significant legal or regulatory issues that investors should be aware of?

Yes, Johnson & Johnson faces numerous ongoing legal proceedings, including product liability claims for various drugs and medical devices, patent litigation related to its medical device products, and investigations into marketing practices. While the company believes these matters, net of accrued liabilities, will not materially adversely affect its financial position, resolution of certain cases could significantly impact operational results and cash flows in a given period.

JNJ 10-Q Quarterly Report Q3 FY2007 — Revenue, Net Income, EPS

Summary

Johnson & Johnson reported robust sales growth in the second quarter of 2007, with a 13.2% increase year-over-year to $15.1 billion. This growth was driven by strong performance across all three business segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. The Consumer segment saw a remarkable 48.6% jump in sales, significantly boosted by the acquisition of Pfizer's consumer healthcare business. The Pharmaceutical segment delivered a solid 5.8% sales increase, with key products like TOPAMAX(R), REMICADE(R), and CONCERTA(R) showing strong operational growth, though some products faced generic competition. The company also highlighted an increase in operating profit margin for the Pharmaceutical segment. However, the Medical Devices & Diagnostics segment experienced a significant decline in operating profit margin year-over-year, primarily due to integration costs related to acquisitions and notable in-process R&D charges. Despite this, overall net earnings for the quarter rose to $3.1 billion from $2.8 billion in the prior year, with diluted EPS increasing to $1.05 from $0.95. The company also announced a significant cost-savings initiative expected to generate substantial annual savings starting in 2008, alongside a new $10 billion stock repurchase program.

Key Highlights

1Total sales increased by 13.2% to $15.1 billion in the fiscal second quarter of 2007, compared to $13.4 billion in the prior year.
2The Consumer segment experienced a substantial sales increase of 48.6%, largely attributed to the acquisition of Pfizer's consumer healthcare business.
3Net earnings for the second quarter rose to $3.1 billion, a 9.3% increase from $2.8 billion in the same period last year.
4Diluted earnings per share (EPS) improved to $1.05, up from $0.95 in the second quarter of 2006.
5The Pharmaceutical segment saw sales growth of 5.8%, driven by strong performance in key drugs like TOPAMAX(R) and REMICADE(R), despite facing generic competition for some products.
6The company announced initiatives expected to generate $1.3-$1.6 billion in pre-tax annual cost savings by 2008, with associated restructuring charges in the second half of 2007.
7A new $10 billion stock repurchase program was authorized, indicating a commitment to returning capital to shareholders.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Jul 1, 2007

Summary

Key Highlights

Frequently Asked Questions